CYBA as a Potential Biomarker for Renal Cell Carcinoma: Evidence from an Integrated Genetic Analysis

Cancer Genomics Proteomics. 2023 Sep-Oct;20(5):469-475. doi: 10.21873/cgp.20398.

Abstract

Background/aim: Oxidative stress plays an important role in various pathogenic processes, and disruption in the coordinated production of NADPH oxidase (NOX)-derived reactive oxygen species has been associated with carcinogenesis. However, little is known about whether genetic variants in NOX can contribute to the development of renal cell carcinoma (RCC).

Patients and methods: This study aimed to bridge this knowledge gap by analysing the association of 10 single-nucleotide polymorphisms in the phagocyte NOX genes, CYBA and CYBB, with RCC risk and tumour characteristics in 630 RCC patients and controls. Differential gene expression and patient prognosis analyses were performed using gene expression data obtained from public databases.

Results: Multivariate analysis and multiple testing corrections revealed the A allele of rs7195830 in CYBA to be a significant risk allele for RCC, compared to the G allele [odds ratio (OR)=1.70, 95% confidence interval (CI)=1.27-2.26, p<0.001]. A pooled analysis of 17 renal cancer gene expression datasets revealed a higher CYBA expression in RCC than in normal tissues. Moreover, high CYBA expression was associated with advanced tumour characteristics and worse patient prognosis.

Conclusion: CYBA might play an oncogenic role in RCC and serve as a predictive indicator of patient prognosis.

Keywords: NADPH oxidase; Renal cell carcinoma; differentially expressed gene; prognosis; single-nucleotide polymorphism.

MeSH terms

  • Biomarkers
  • Carcinoma, Renal Cell* / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • NADPH Oxidases / genetics
  • Polymorphism, Single Nucleotide

Substances

  • NADPH Oxidases
  • Biomarkers
  • CYBA protein, human